Antithrombotic efficacy of thrombin inhibitor L-374,087: Intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 503-510

  Cook, Jacquelynn J ^a   Gardell, Stephen J ^a   Holahan, Marie A ^a   Sitko, Gary R ^a   Stump, Gary L ^a   Wallace, Audrey A ^a   Gilberto, David B ^a   Hare, Timothy R ^a   Krueger, Julie A ^a   Dyer, Dona L ^a   Sanderson, Philip E J ^a   Vacca, Joseph P ^a   Shafer, Jules A ^a   Lynch Jr , Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 AMINO 6 METHYL 5 PYRIDINYLMETHYLAMINOCARBONYLMETHYL) 3 BENZYLSULFONAMIDO 6 METHYL 2 PYRIDINONE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; INTRAVENOUS DRUG ADMINISTRATION; JUGULAR VEIN; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RHESUS MONKEY; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANESTHESIA; ANIMALS; BLEEDING TIME; BLOOD COAGULATION; CORONARY THROMBOSIS; DOGS; FEMALE; FIBRINOLYTIC AGENTS; HEMATOCRIT; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; JUGULAR VEINS; MACACA MULATTA; MALE; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PYRIDONES; SULFONAMIDES; THROMBIN; VENOUS THROMBOSIS;

EID: 0032892945     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Agnelli G and Sonaglia F (1997) Prevention of venous thromboembolism in high risk patients. Haematalogica 82:496-502.
2. Antman EM for the TIMI 9A Investigators (1994) Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 90:1624-1630.
3. Antman EM for TIMI 9B Investigators (1996) Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94:911-921.
4. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E and Adelman B for the Hirulog Angioplasty Study Investigators (1995) Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 333: 764-769.
5. Brady SF, Lewis SD, Colton CD, Stauffer KJ, Sisko JT, Ng AS, Homnick CF, Bogusky MJ, Shafer JA, Veber DF and Nutt RF (1995) Development of highly potent and selective α-keto carbonyl thrombin inhibitors with novel P1 side chains, in Peptides: Chemistry, Structure and Biology (Proceedings of the Fourteenth American Peptide Symposium) (Kaumaya PTP and Hodges RS eds) pp 331-333, Mayflower Scientific Ltd., England.
6. Brady SF, Stauffer KJ, Lumma WC, Smith GM, Ramjit HG, Lewis SD, Lucas BJ, Gardell SJ, Lyle EA, Appleby SD, Cook JJ, Holahan MA, Stranieri MT, Lynch JJ, Lin JH, Chen I-W, Vastag K, Naylor-Olsen AM and Vacca JP (1998) Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): Co-application of structure-based design and rapid multiple analog synthesis on solid support. J Med Chem 41:401-406.
7. Challapalli R, Lefkovits J and Topol EJ (1996) Clinical trials of recombinant hirudin in acute coronary syndromes. Coron Artery Dis 7:429-437.
8. Coller BS, Folts JD, Smith SR, Scudder LE and Jordan R (1989) Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 80:1766-1774.
9. Cook JJ, Sitko GR, Bednar B, Condra C, Mellott MJ, Feng D-M, Nutt RF, Shafer JA, Gould RJ and Connolly TM (1995) An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 91:2961-2971.
10. Cook JJ, Holahan MA, Lyle EA, Ramjit DR, Sitko GR, Stranieri MT, Stupienski RF, Wallace AA, Hand EL, Gilbert JD, Gehret JR, Kothstein T, Drag MD, McCormick GY, Perkins JJ, Ihle NC, Duggan ME, Hartman GD, Gould RJ and Lynch JJ (1996) Non-peptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther 278:62-73.
11. Cousins GR, Friedrichs GS, Sudo Y, Rebello SS, Rote WE, Vlasuk GP, Nolan TG, Mendoza C and Lucchesi BR (1996) Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. Circulation 94:1705-1712.
12. Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Kalebo P and Close P (1997a) Prevention of thromboembolism with use of recombinant hirudin: Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg 79:A326-A333.
13. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S and Close P (1997b) A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337:1329-1335.
14. Feng D-M, Gardell SJ, Lewis SD, Bock MG, Chen Z, Freidinger RM, Naylor-Olsen AM, Ramjit HG, Woltmann R, Baskin EP, Lynch JJ, Lucas R, Shafer JA, Dancheck KB, Chen I-W, Mao S-S, Krueger JA, Hare TR, Mulichak AM and Vacca JP (1997) Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. J Med Chem 40:3726-3733.
15. FitzGerald GA (1996) The human pharmacology of thrombin inhibition. Coron Artery Dis 7:911-918.
16. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG, Weitz J, Buller HR, ten Cate JW, Neemeh J, Adelman B, Fox I, Maraganore J and Hirsch J (1994) Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 90:2385-2389.
17. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators (1994) Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631-1637.
18. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775-782.
19. Hirsh J (1991a) Heparin. N Engl J Med 324:1565-1574.
20. Hirsh J (1991b) Oral anticoagulant drugs. N Engl J Med 324:1865-1875.
21. Homeister JW, Mickelson JK, Hoff PT and Lucchesi BR (1991) Recombinant hirudin reduces the incidence of thrombotic occlusion in a canine model of coronary vascular injury. Coron Artery Dis 2:237-246.
22. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR and Harker LA (1991) Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 77:1006-1012.
23. Lind SE (1991) The bleeding time does not predict surgical bleeding. Blood 77:2547-2552.
24. Lyle TA, Chen Z, Appleby SD, Freidinger RM, Gardell SJ, Lewis SD, Li Y, Lyle EA, Lynch JJ, Mulichak AM, Ng AS, Naylor-Olsen AM and Sanders WM (1997) Synthesis, evaluation and crystallographic analysis of L-371.912: A potent and selective active-site thrombin inhibitor. Bioorg Med Chem Lett 7:67-72.
25. Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ, Manno PD, Chang CT-C, Egbertson MS, Halczenko W, Duggan ME, Laswell WL, Vassallo LM, Shafer JA, Anderson PS, Friedman PA, Hartman GD and Gould RJ (1995) Non-peptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther 272:20-32.
26. Maraganore JM and Adelman BA (1996) Hirulog: A direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 7:438-446.
27. 2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 21:393-405.
28. Neuhaus K-L, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H and Horacek T (1994) Safety observations from the pilot phase of the Randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 90:1638-1642.
29. Organization of Assess Strategies for Ischemic Syndromes (OASIS) Investigators (1997) Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Circulation 96:769-777.
30. Rebello SS, Miller BV, Basler GC and Lucchesi BR (1997) CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol 29:240-249.
31. Ripka WC and Vlasuk GP (1997) Antithrombotics/serine proteases. Ann Rep Med Chem 32:71-89.
32. Sanderson PEJ, Cutrona KJ, Dorsey BD, Dyer DL, McDonough CM, Naylor-Olsen AM, Chen I-W, Chen Z, Cook JJ, Gardell SJ, Krueger JA, Lewis SD, Lin JH, Lucas BJ, Lyle EA, Lynch JJ, Stranieri MT, Vastag K, Shafer JA and Vacca JP (1998) L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Lett 8:817-822.
33. Sanderson PEJ, Dyer DL, Naylor-Olsen AM, Vacca JP, Gardell SJ, Lewis SD, Lucas BJ, Lyle EA, Lynch JJ and Mulichak AM (1997) L-373,890, an achiral, noncovalent, subnanomolar thrombin inhibitor. Bioorg Med Chem Lett 7:1497-1500.
34. Serruys PW, Herrman, J-PR., Simon R, Rutsch W, Bode C, Laarman G-J, van Dijk R, van den Bos AA, Umans VAWM, Fox KAA., Close P and Deckers JW for the Helvetical Investigators (1995) A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 333:757-763.
35. Toschi V, Lettino M, Gallo R, Badimon JJ and Chesebro JH (1996) Biochemistry and biology of hirudin. Coron Artery Dis 7:420-428.
36. Tucker TJ, Lumma WC, Lewis SD, Gardell SJ, Lucas BJ, Sisko JT, Lynch JJ, Lyle EA, Baskin EP, Woltmann RF, Appleby SD, Chen I-W, Dancheck KB, Naylor-Olsen, AM, Krueger JA, Cooper CM and Vacca JP (1997) Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilized 3,3-disubstituted propionic acid derivatives in the P3 position. J Med Chem 40:3687-3693.
37. Weitz JI (1996) Biological rationale for the therapeutic role of specific antithrombins. Coron Artery Dis 7:409-419.
38. Weitz JI (1997) Low molecular weight heparins. N Engl J Med 337:688-698.
39. White HD, Aylward PE, Frey MJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J and Adelman B on behalf of the HERO Investigators (1997) Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 96:2155-2161.